Published in Cancer Weekly, December 23rd, 2003
The purchasers included both institutional investors and high net worth individuals. In the placement, 12.2 million shares of common stock were issued at $0.23 per share, as well as Series R warrants to purchase additional 6.1 million common shares at $0.28 per share. The warrants have a term of five years. The company has agreed to file a registration statement covering resales of the securities by the purchasers to the public no later than December 31, 2003.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.